Your Health, We Care
Release date: 2026-06-24 14:40:35 Recommended: 7
May cause fetal harm. Effective contraception must be used during treatment and for at least 1 week after the last dose.
Immediately inform your doctor to assess the risks and benefits of continuing therapy, and adjust the treatment plan if necessary.
It is unknown whether momelotinib is excreted in human milk. Do not breastfeed during treatment and for 1 week after the last dose; discuss appropriate alternative infant feeding methods with your doctor.
It is recommended to discuss fertility planning with your doctor in advance. You may need to switch medications or arrange a washout period before attempting conception to reduce fetal exposure risk.
Include prescription drugs, over‑the‑counter medications, vitamins, and herbal supplements (e.g., Chinese patent medicines, health products).
Strong CYP3A4 inhibitors or inducers may alter the metabolic clearance rate of momelotinib.
Certain antifungals (e.g., ketoconazole), antibiotics (e.g., clarithromycin), antiepileptics (e.g., carbamazepine), etc.
Your doctor will adjust the dose or suggest switching concomitant medications based on the interaction severity. Do not add any new drugs on your own; even over‑the‑counter cold remedies should be first reviewed with a pharmacist or physician.
When visiting a new specialty clinic or purchasing new medications, routinely review your medication list to ensure safety.
Janus kinases (JAKs) are intracellular signal transduction proteins that are particularly abundant in bone marrow hematopoietic stem cells.
In patients with myelofibrosis, mutations in bone marrow cell DNA lead to abnormally hyperactive JAK signaling pathways, triggering inflammatory responses and promoting fibrous tissue proliferation (fibrosis), which replaces normal hematopoietic tissue and reduces production of healthy blood cells.
As a JAK inhibitor, momelotinib binds to overactive JAK proteins, blocking aberrant signal transduction and suppressing inflammation and fibrotic progression.
It can reduce splenomegaly, improve systemic symptoms, and may restore some normal hematopoietic function.
Unlike conventional JAK inhibitors, momelotinib possesses a distinctive dual‑inhibitory property.
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
